---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016905"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:46:59.786129+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q2 2022 net loss $13.5M; cash $122.1M; NMIBC trial on track

## Summary
- Net loss $13.5M for Q2 2022 vs $8.9M in Q2 2021; R&D expense rose to $9.5M from $6.6M.
- Cash and equivalents $122.1M; sufficient to fund operations into 2024.
- On track to dose first patient in Phase 1 NMIBC trial in Q3 2022; FDA Fast Track granted.
- On track to initiate pivotal trial in early-stage choroidal melanoma in Q4 2022.
- Plans to file IND for choroidal metastases in Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-016905
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/0000950170-22-016905-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017022016905/aura-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016905
- JSON: https://secwatch.observer/filing/0000950170-22-016905.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016905.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.